Corcept Therapeutics (CORT) Gross Profit (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Gross Profit data on file, last reported at $162.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 4.66% year-over-year to $162.0 million; the trailing twelve-month figure through Mar 2026 stood at $755.6 million (up 12.0% YoY), and the FY2025 full-year result was $748.4 million, up 12.69% from the prior year.
• Gross Profit fell to $162.0 million in Q1 2026, from $199.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $203.0 million in Q3 2025 to a low of $92.4 million in Q1 2022.
• A 5-year average of $143.9 million and a median of $144.3 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit gained 4.21% in 2022 and surged 47.33% in 2024, its largest moves.
• Tracing CORT's Gross Profit over 5 years: stood at $101.6 million in 2022, then jumped by 31.46% to $133.5 million in 2023, then surged by 34.0% to $178.9 million in 2024, then advanced by 11.54% to $199.6 million in 2025, then fell by 18.82% to $162.0 million in 2026.
• Business Quant data shows CORT's Gross Profit at $162.0 million in Q1 2026, $199.6 million in Q4 2025, and $203.0 million in Q3 2025.